Showing 7121-7130 of 9550 results for "".
- Skin Color Affects Skin Sensitivity to Heat and Mechanical Stimulihttps://practicaldermatology.com/news/skin-color-affects-skin-sensitivity-to-heat-and-mechanical-stimuli/2458069/Researchers at the Bluestone Center for Clinical Research at the New York University College of Dentistry (NYU Dentistry) have identified a novel molecular mechanism which explains why dark-skinned and light-skinned people respond differently to heat and mechanical stimulation. In a study
- Colorescience Takes Aim at Rosacea with All Calm™ Clinical Redness Correctorhttps://practicaldermatology.com/news/colorescience-takes-aim-at-rosacea-with-all-calm-clinical-redness-corrector/2458082/Colorescience® is introducing All Calm™ Clinical Redness Corrector. Available Colorescience.com, all Calm Clinical Redness Corrector helps neutralize redness with its subtle green undertones. The patent-pending BioSolaceTM complex
- Protea Expands Clinical Study for New Melanoma Testhttps://practicaldermatology.com/news/protea-expands-clinical-study-for-new-melanoma-test/2458083/Protea Biosciences Group, Inc. is expanding its clinical research study for their new molecular imaging test for the differential diagnosis of malignant melanoma. The study has now surpassed 250 patient samples, the company reports. The propr
- Women of Color May Be Disproportionately Exposed to Beauty Product Chemicalshttps://practicaldermatology.com/news/women-of-color-may-be-disproportionately-exposed-to-beauty-product-chemicals/2458087/Women with skin of color have higher levels of beauty-product related chemicals in their bodies compared to white women, according to a commentary published in the American Journal of Obstetrics and Gynecology.<
- FDA Advisory Arm Backs XELJANZ for PsAhttps://practicaldermatology.com/news/fda-advisory-arm-backs-xeljanz-for-psa/2458098/The United States Food and Drug Administration’s (FDA) Arthritis Advisory Committee recommends the approval of Pfizer's XELJANZ® (tofacitinib) for the treatment of adults with active psoriatic arthritis (PsA). The Arthritis Advisory Commit
- Boehringer Ingelheim Begins Interchangeability Study Between Adalimumab Biosim and Humirahttps://practicaldermatology.com/news/boehringer-ingelheim-begins-interchangeability-study-between-adalimumab-biosim-and-humira/2458106/The first patient has been enrolled into the VOLTAIRE-X interchangeability study, which seeks to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40 mg/0.8 ml. This is the first study in the U.S. to investigate an interchange
- Valeant's Newly Minted Ortho Dermatologic Unit Makes Big Splash at Summer AADhttps://practicaldermatology.com/news/valeants-newly-minted-orthodermatologic-division-makes-a-big-splash-at-summer-aad/2458105/It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division. At the 2017 American Academy of Dermatology in New York City, the company will officially launch Siliq (brodalumab) for psoriasis and announce their new name change. Dermwire
- Histogen's Growth Factor Technology Now Part of Allergan's Skin Care Linehttps://practicaldermatology.com/news/histogens-growth-factor-technology-now-part-of-allergan-skin-care-line/2458111/Histogen’s growth factor technology will be marketed as part of Allergan's skin care line within its recently acquired Regenica® Advanced Rejuvenation System. The Regenica line is based on multipotent CCM Complex (Cell Conditioned Media) which comprises active growth factors
- Syneron Candela Completes Transaction with Funds Advised by Apax Partners; Becomes a Private Companyhttps://practicaldermatology.com/news/syneron-candela-completes-transaction-with-funds-advised-by-apax-partners-becomes-a-private-company/2458121/Syneron Medical Ltd. announced the successful completion of its acquisition by an affiliate of funds advised by Apax Partners for $11.00 per share in cash in a transaction valued at approximately $400 million. The transacti
- FDA Approves Janssen's Tremfya for Moderate To Severe Plaque Psoriasishttps://practicaldermatology.com/news/fda-approves-janssens-tremfya-for-moderate-to-severe-plaque-psoriasis/2458123/The FDA has approved Janssen's Tremfya (guselkumab) for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Tremfya is the first and only approved biologic therapy that selectively blocks only IL-23, a cytokine that plays a